Clair Blacketer

Mrs. Clair Blacketer


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
MHMelissa A Haendel
Melissa A Haendel
CCChristopher G Chute
Christopher G Chute
TBTellen D Bennett
Tellen D Bennett
DEDavid A Eichmann
David A Eichmann
JGJustin Guinney
Justin Guinney
EHElaine L Hill
Elaine L Hill
Objective: Coronavirus disease 2019 (COVID-19) poses societal challenges that require expeditious data and knowledge sharing. Though organizational clinical data are abundant, these are largely inaccessible to outside researchers. Statistical, machine learning, and causal analyses are most successful with large-scale data beyond what is available in any given organization. Here, we introduce the National COVID Cohort Collaborative (N3C), an open science community focused on analyzing patient-level data from many centers.Materials and Methods: The Clinical and Translational Science Award Program and scientific community created N3C to overcome technical, regulatory, policy, and governance barriers to sharing and harmonizing individual-level clinical data. We developed solutions to extract, aggregate, and harmonize data across organizations and data models, and created a secure data enclave to enable efficient, transparent, and reproducible collaborative analytics.Results: Organized in inclusive workstreams, we created legal agreements and governance for organizations and researchers; data extraction scripts to identify and ingest positive, negative, and possible COVID-19 cases; a data quality assurance and harmonization pipeline to create a single harmonized dataset; population of the secure data enclave with data, machine learning, and statistical analytics tools; dissemination mechanisms; and a synthetic data pilot to democratize data access.Conclusions: The N3C has demonstrated that a multisite collaborative learning health network can overcome barriers to rapidly build a scalable infrastructure incorporating multiorganizational clinical data for COVID-19 analytics. We expect this effort to save lives by enabling rapid collaboration among clinicians, researchers, and data scientists to identify treatments and specialized care and thereby reduce the immediate and long-term impacts of COVID-19.

27 July 2021 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
CBClair Blacketer
Clair Blacketer
FDFrank J Defalco
Frank J Defalco
PRPatrick B Ryan
Patrick B Ryan
PRPeter R Rijnbeek
Peter R Rijnbeek
Objective: Advances in standardization of observational healthcare data have enabled methodological breakthroughs, rapid global collaboration, and generation of real-world evidence to improve patient outcomes. Standardizations in data structure, such as use of common data models, need to be coupled with standardized approaches for data quality assessment. To ensure confidence in real-world evidence generated from the analysis of real-world data, one must first have confidence in the data itself. Materials and Methods: We describe the implementation of check types across a data quality framework of conformance, completeness, plausibility, with both verification and validation. We illustrate how data quality checks, paired with decision thresholds, can be configured to customize data quality reporting across a range of observational health data sources. We discuss how data quality reporting can become part of the overall real-world evidence generation and dissemination process to promote transparency and build confidence in the resulting output. Results: The Data Quality Dashboard is an open-source R package that reports potential quality issues in an OMOP CDM instance through the systematic execution and summarization of over 3300 configurable data quality checks. Discussion: Transparently communicating how well common data model-standardized databases adhere to a set of quality measures adds a crucial piece that is currently missing from observational research. Conclusion: Assessing and improving the quality of our data will inherently improve the quality of the evidence we generate.

1 July 2020 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
MCM. Soledad Cepeda
M. Soledad Cepeda
DKDavid M. Kern
David M. Kern
CBClair Blacketer
Clair Blacketer
WDWayne C. Drevets
Wayne C. Drevets
Reports suggest low levels of cholesterol are associated with depression. However, results have not been replicated, the direction of the associations among types of cholesterol levels is not consistent, there is large study heterogeneity, and many studies have small samples. The objective of the study was to assess the association of cholesterol with depression. This is a cross-sectional study using the National Health and Nutrition Examination Survey (NHANES). The NHANES is a research program that collects health information from a representative U.S. We included subjects aged ≥18 years who responded to NHANES surveys from 2009 to 2015. Subjects were classified as having major depression if the Patient Health Questionnaire scores were ≥10. Exposures were total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. We considered the age, body mass index, gender, smoking, alcohol use, health status, and exposure to statins and antipsychotics as potential confounders. To assess the association of the exposures with depression, we used decision tree and logistic regression models. A total of 19,527 subjects were analyzed, and 8% had depression. Subjects with depression were more likely to be women and smokers, and to have higher body mass index, poor health, higher levels of total cholesterol and triglycerides and lower levels of high-density lipoprotein cholesterol than subjects with no depression. After adjustment, low levels of total cholesterol (<129 mg/dL) were associated with decreased risk of depression compared with higher levels, OR = 0.64 and 95% CI (0.42-0.98). This large population-based study found no association of low cholesterol or any other lower type of cholesterol levels with increased risk of depression. These findings are generalizable to the U.S.

10 November 2023 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
EVErica A Voss
Erica A Voss
CBClair Blacketer
Clair Blacketer
SSSebastiaan van Sandijk
Sebastiaan van Sandijk
MMMaxim Moinat
Maxim Moinat
MKMichael Kallfelz
Michael Kallfelz
PRPeter R Rijnbeek
Peter R Rijnbeek
Objective: Health data standardized to a common data model (CDM) simplifies and facilitates research. This study examines the factors that make standardizing observational health data to the Observational Medical Outcomes Partnership (OMOP) CDM successful. Materials and methods: Twenty-five data partners (DPs) from 11 countries received funding from the European Health Data Evidence Network (EHDEN) to standardize their data. Three surveys, DataQualityDashboard results, and statistics from the conversion process were analyzed qualitatively and quantitatively. Our measures of success were the total number of days to transform source data into the OMOP CDM and participation in network research. Results: The health data converted to CDM represented more than 133 million patients. 100%, 88%, and 84% of DPs took Surveys 1, 2, and 3. The median duration of the 6 key extract, transform, and load (ETL) processes ranged from 4 to 115 days. Of the 25 DPs, 21 DPs were considered applicable for analysis of which 52% standardized their data on time, and 48% participated in an international collaborative study. Discussion: This study shows that the consistent workflow used by EHDEN proves appropriate to support the successful standardization of observational data across Europe. Over the 25 successful transformations, we confirmed that getting the right people for the ETL is critical and vocabulary mapping requires specific expertise and support of tools. Additionally, we learned that teams that proactively prepared for data governance issues were able to avoid considerable delays improving their ability to finish on time. Conclusion: This study provides guidance for future DPs to standardize to the OMOP CDM and participate in distributed networks. We demonstrate that the Observational Health Data Sciences and Informatics community must continue to evaluate and provide guidance and support for what ultimately develops the backbone of how community members generate evidence.

6 September 2021 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
SKSara Khalid
Sara Khalid
CYCynthia Yang
Cynthia Yang
CBClair Blacketer
Clair Blacketer
TDTalita Duarte-Salles
Talita Duarte-Salles
SFSergio Fernández-Bertolín
Sergio Fernández-Bertolín
JRJenna M. Reps
Jenna M. Reps
As a response to the ongoing COVID-19 pandemic, several prediction models in the existing literature were rapidly developed, with the aim of providing evidence-based guidance. However, none of these COVID-19 prediction models have been found to be reliable. Models are commonly assessed to have a risk of bias, often due to insufficient reporting, use of non-representative data, and lack of large-scale external validation. In this paper, we present the Observational Health Data Sciences and Informatics (OHDSI) analytics pipeline for patient-level prediction modeling as a standardized approach for rapid yet reliable development and validation of prediction models. We demonstrate how our analytics pipeline and open-source software tools can be used to answer important prediction questions while limiting potential causes of bias (e.g., by validating phenotypes, specifying the target population, performing large-scale external validation, and publicly providing all analytical source code). We show step-by-step how to implement the analytics pipeline for the question: ‘In patients hospitalized with COVID-19, what is the risk of death 0 to 30 days after hospitalization?’. We develop models using six different machine learning methods in a USA claims database containing over 20,000 COVID-19 hospitalizations and externally validate the models using data containing over 45,000 COVID-19 hospitalizations from South Korea, Spain, and the USA. Our open-source software tools enabled us to efficiently go end-to-end from problem design to reliable Model Development and evaluation. When predicting death in patients hospitalized with COVID-19, AdaBoost, random forest, gradient boosting machine, and decision tree yielded similar or lower internal and external validation discrimination performance compared to L1-regularized logistic regression, whereas the MLP neural network consistently resulted in lower discrimination. L1-regularized logistic regression models were well calibrated. Our results show that following the OHDSI analytics pipeline for patient-level prediction modelling can enable the rapid development towards reliable prediction models. The OHDSI software tools and pipeline are open source and available to researchers from all around the world.

26 March 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SSSeo Jeong Shin
Seo Jeong Shin
SYSeng Chan You
Seng Chan You
YPYu Rang Park
Yu Rang Park
JRJin Roh
Jin Roh
JKJang-Hee Kim
Jang-Hee Kim
Rae Woong ParkRae Woong Park
Rae Woong Park
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Clinical sequencing data should be shared so as to achieve the sufficient scale and diversity required for providing strong evidence toward improving patient care. A distributed research network (DRN) allows researchers to share this evidence rather than the patient-level data across centers, thereby avoiding privacy issues. The Observational Medical Outcomes Partnership (OMOP) common data model (CDM), currently used in DRNs, has low coverage of sequencing data and does not reflect the latest trend of precision medicine. Objective: The aim of this study was to develop and evaluate the feasibility of a genomic CDM (G-CDM), as an extension of the OMOP-CDM, for application of genomic data in clinical practice. Methods: Existing genomic data models and sequencing reports were reviewed to extend the OMOP-CDM to cover genomic data. Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC) and Human Genome Variation Society (HGVS) nomenclature was adopted to standardize the terminology in the model. Sequencing data of 114 and 1060 patients with lung cancer were obtained from the Ajou University School of Medicine (AUSOM) database of Ajou University Hospital and The Cancer Genome Atlas (TCGA), respectively, which were transformed to a format appropriate for the G-CDM. The data were compared with respect to gene name, variant type, and actionable mutations. Results: The G-CDM was extended into four tables linked to tables of the OMOP-CDM. Upon comparison with TCGA data, a clinically actionable mutation, ‘p.Leu858Arg’, in the EGFR gene was 6.64-times more frequent in the AUSOM database, while the ‘p.Gly12Xaa’ mutation in the KRAS gene was 2.02-times more frequent in the TCGA dataset. The data-exploring tool GeneProfiler was further developed to conduct descriptive analyses automatically using the G-CDM, which provides the proportions of genes, variant types, and actionable mutations. GeneProfiler also allows for querying the specific gene name and HGVS nomenclature to calculate the proportion of patients with a given mutation. Conclusions: We developed the G-CDM for effective integration of genomic data with standardized clinical data allowing for data sharing across institutes. The feasibility of the G-CDM was validated by assessing the differences in data characteristics between two different genomic databases through the proposed data-exploring tool, GeneProfiler. The G-CDM may facilitate analyses of interoperating clinical and genomic datasets across multiple institutions, minimizing privacy issues and thereby enabling researchers to better understand the characteristics of patients and promote personalized medicine in clinical practice.